Comparing Safety and Efficacy of “Third-Generation” Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment

CNS Drugs

Volumn 31, Issue 11, 2017, Pages 959-974

  Kwok, Charlotte S ^a   Johnson, Emily L ^a   Krauss, Gregory L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; ESLICARBAZEPINE ACETATE; LACOSAMIDE; PERAMPANEL; 2 PYRROLIDONE DERIVATIVE; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; DIBENZAZEPINE DERIVATIVE; PYRIDONE DERIVATIVE;

ANESTHESIA COMPLICATION; ANTICONVULSANT THERAPY; ASTHENIA; ATRIAL FIBRILLATION; BEHAVIOR DISORDER; CONFUSION; CONTUSION; CONVULSION; DEPRESSION; DIPLOPIA; DISRUPTIVE BEHAVIOR; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EMOTIONAL DISORDER; EPILEPTIC STATE; FAINTNESS; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPONATREMIA; INSOMNIA; INSTABILITY; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBLEM BEHAVIOR; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; UNSTEADINESS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VISUAL HALLUCINATION; VOMITING; WALKING DIFFICULTY; ADVERSE DRUG REACTION; FOLLOW UP; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; POSTMARKETING SURVEILLANCE;

ACETAMIDES; ANTICONVULSANTS; DIBENZAZEPINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDONES; PYRROLIDINONES; SEIZURES;

EID: 85036556867     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-017-0480-6     Document Type: Review

References (70)

1. US Food and Drug Administration. Step 3: clinical research. US Food Drug Administration. [Internet]. 2015; pp 1–4. http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_Research_Phase_Studies. Accessed 9 Aug 2017.
2. Rosenfeld W, Fountain NB, Kaubrys G, Ben-Menachem E, Mcshea C, Isojarvi J, et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav. 2014;41:164–70. https://doi.org/10.1016/j.yebeh.2014.09.074.
3. Edwards HB, Cole AG, Griffiths AS, Lin B, Bean A, Krauss GL. Minimizing pharmacodynamic interactions of high doses of lacosamide. Acta Neurol Scand. 2012;125:228–33.
4. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J. 1997;314:180–1.
5. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology [Internet]. 1998;50:614–8. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=9521245&site=ehost-live. Accessed 9 Aug 2017.
6. ® registry 5-year results: characteristics of adult patients treated with vigabatrin. Epilepsy Behav [Internet]. 2016;56:15–9. https://doi.org/10.1016/j.yebeh.2015.12.004.
7. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ [Internet]. 1995; 311:619–20. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2550668&tool=pmcentrez&rendertype=abstract. Accessed 9 Aug 2017.
8. Thakkar K, Billa G, Rane J, Chudasama H, Goswami S, Shah R. The rise and fall of felbamate as a treatment for partial epilepsy—aplastic anemia and hepatic failure to blame? Expert Rev Neurother Inform Healthc. 2015;15:1373–5.
9. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98:1366–71 (American Public Health Association).
10. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308–17.
11. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51:958–67.
12. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.
13. Biton V. Lacosamide for the treatment of partial-onset seizures. Expert Rev. Neurother. [Internet]. 2012;12: 645–55. http://www.expert-reviews.com/doi/abs/10.1586/ern.12.50?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed. Accessed 9 Aug 2017.
14. Sake JK, Hebert D, Isojrvi J, Doty P, De Backer M, Davies K, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055–68.
15. Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial. Epilepsia. 2012;53:521–8.
16. Rosenow F, Kelemen A, Ben-Menachem E, Mcshea C, Isojarvi J, Doty P, et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016;133:136–44.
17. Vossler DG, Wechsler RT, Williams P, Byrnes W, Therriault S. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: results from a multicenter, open-label trial. Epilepsia. 2016;57:1625–33.
18. Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure. 2013;22:210–6.
19. Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–4.
20. Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol [Internet]. 2014; 18:55–9. http://www.scopus.com/inward/record.url?eid=2-s2.0-84892507265&partnerID=40&md5=5f28e91dc70822f386224ea1ccc93091. Accessed 9 Aug 2017.
21. Kim JS, Kim H, Lim BC, Chae J-H, Choi J, Kim KJ, et al. Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain Dev. 2014;36:510–5.
22. García-Morales I, Delgado RT, Falip M, Campos D, García ME, Gil-Nagel A. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure. 2011;20:801–4.
23. Giraldez BG, Toledano R, Garcia-Morales I, Gil-Nagel A, Lopez-Gonzalez FJ, Tortosa D, et al. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation. Seizure [Internet]. 2015; 29:119–22. http://www.elsevier.com/inca/publications/store/6/2/3/0/7/1/index.htt%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed17&AN=604863003%5Cnhttp://www.tdnet.com/AalSy/resolver?sid=OVID:embase&id=pmid:26076854&id=doi:10.1016%2Fj.se. Accessed 9 Aug 2017.
24. Toupin J-F, Lortie A, Major P, Diadori P, Vanasse M, Rossignol E, et al. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre. Epileptic Disord. 2015;17:436–43.
25. Andrade-Machado R, Luque-Navarro-De Los Reyes J, Benjumea-Cuartas V, Restrepo JFA, Jaramillo-Jiménez E, Andrade-Gutierrez G, et al. Efficacy and tolerability of add-on lacosamide treatment in adults with Lennox-Gastaut syndrome: an observational study. Seizure. 2015;33:81–7.
26. Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. Epilepsy Behav. [Internet]. 2017; 58:35–43. https://doi.org/10.1016/j.yebeh.2016.02.041.
27. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058–68.
28. French JA, Krauss GL, Wechsler RT, Wang X-F, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology [Internet]. 2015; 85:950–7. http://www.ncbi.nlm.nih.gov/pubmed/26296511%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4567458. Accessed 9 Aug 2017.
29. French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589–96.
30. French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117–25.
31. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurol. [Internet]. 2012; 78:1408–15. http://www.neurology.org/content/78/18/1408.abstract. Accessed 9 Aug 2017.
32. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–9.
33. Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125:8–15.
34. Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126:263–9.
35. Juhl S, Rubboli G. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience. Acta Neurol Scand. 2016;134:374–7.
36. Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201–10.
37. Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav. 2016;61:41–5.
38. Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, Schelhaas HJ, Majoie MHJM. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav. 2017;66:64–7.
39. Maurousset A, Limousin N, Praline J, Biberon J, Corcia P, De Toffol B. Adjunctive perampanel in refractory epilepsy: experience at tertiary epilepsy care center in Tours. Epilepsy Behav. 2016;61:237–41.
40. Tambucci R, Basti C, Maresca M, Coppola G, Verrotti A. Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy. Neuropsychiatr. Dis. Treat. 2016;12:1251–60.
41. Shirley M, Dhillon S. Eslicarbazepine acetate monotherapy: a review in partial-onset seizures. Drugs. 2016;76:707–17 (Springer International Publishing).
42. Gama H, Vieira M, Costa R, Graça J, Magalhães LM, Soares-da-Silva P. Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience. Drug Saf. 2017; vol 40, pp 1–10 (Springer International Publishing).
43. Gil-Nagel A, Elger C, Ben-Menachem E, Halász P, Lopes-Lima J, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013;54:98–107 (Blackwell Publishing Ltd).
44. Elger C, Halász P, Maia J, Almeida L, Soares-Da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63.
45. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:278–85.
46. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120:281–7 (Blackwell Publishing Ltd).
47. Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56:244–53.
48. Rocamora R. A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. Ther Adv Neurol Disord. 2015;8:178–86 (SAGE Publications).
49. U.S. Food and Drug Administration/Center for Drug Evaluation and Research. NDA 22416 Aptiom/Eslicarbazepine Acetate. [Internet]. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416orig1s000medr.pdf. Accessed Aug 2017.
50. Jacobson MP, Pazdera L, Bhatia P, Grinnell T, Cheng H, Blum D, et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol. 2015;15:46.
51. Sperling MR, Harvey J, Grinnell T, Cheng H, Blum D. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Epilepsia. 2015;56:546–55.
52. Halasz P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010;51:1963–9 (Blackwell Publishing Ltd).
53. Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013;103:262–9 (Elsevier B.V.).
54. Correia FD, Freitas J, Magalhães R, Lopes J, Ramalheira J, Lopes-Lima J, et al. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study. Epilepsy Res. 2014;108:1399–405.
55. Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108:1243–52.
56. Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatremia following esclicarbazepine therapy. Seizure. 2015;29:11–4.
57. French JA, Costantini C, Brodsky A, Von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75:519–25.
58. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54:89–97.
59. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55:47–56.
60. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:57–66.
61. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38–46.
62. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–8.
63. Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57:1139–51.
64. Steinig I, von Podewils F, Möddel G, Bauer S, Klein KM, Paule E, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58:1208–16.
65. Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55:423–31.
66. Biton V, Rogin JB, Krauss G, Abou-Khalil B, Rocha JF, Moreira J, et al. Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials. Epilepsy Behav. 2017;72:127–34 (United States).
67. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–607 (United States).
68. Toledo M, Beale R, Evans JS, Steeves S, Elmoufti S, Townsend R, et al. Long-term retention rates for antiepileptic drugs: a review of long-term extension studies and comparison with brivaracetam. Epilepsy Res. 2017;138:53–61 (Netherlands).
69. Ben-Menachem E, Mameniskiene R, Quarato PP, Klein P, Gamage J, Schiemann J, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87:314–23 (United States).
70. Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–8 (United States).